Alkem Laboratories Limited
Alkem Laboratories Limited (ALKEM) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
alkemlabs.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-02
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,440 Cr | 3,324 Cr | 2,936 Cr | 3,032 Cr | 3,415 Cr | 3,374 Cr | 3,144 Cr | 3,371 Cr | 4,001 Cr | 3,737 Cr | 3,603 Cr | 3,740 Cr |
| Operating expenses (approx.) | 2,693 Cr | 2,616 Cr | 2,534 Cr | 2,423 Cr | 2,662 Cr | 2,615 Cr | 2,752 Cr | 2,632 Cr | 3,080 Cr | 2,909 Cr | 3,086 Cr | 2,974 Cr |
| EBITDA | 747 Cr | 708 Cr | 402 Cr | 609 Cr | 753 Cr | 759 Cr | 391 Cr | 739 Cr | 921 Cr | 828 Cr | 517 Cr | 766 Cr |
| OPM % | 21.7% | 21.3% | 13.7% | 20.1% | 22.0% | 22.5% | 12.4% | 21.9% | 23.0% | 22.2% | 14.4% | 20.5% |
| Other income | 63 Cr | 94 Cr | 88 Cr | 120 Cr | 134 Cr | 93 Cr | 146 Cr | 136 Cr | 104 Cr | 143 Cr | 200 Cr | 153 Cr |
| Interest | 30 Cr | 25 Cr | 27 Cr | 29 Cr | 28 Cr | 36 Cr | 28 Cr | 30 Cr | 35 Cr | 42 Cr | 54 Cr | 47 Cr |
| Depreciation | 74 Cr | 70 Cr | 83 Cr | 80 Cr | 79 Cr | 85 Cr | 112 Cr | 88 Cr | 94 Cr | 95 Cr | 106 Cr | 100 Cr |
| Profit before tax | 648 Cr | 655 Cr | 367 Cr | 619 Cr | 780 Cr | 731 Cr | 396 Cr | 771 Cr | 895 Cr | 781 Cr | 422 Cr | 771 Cr |
| Tax % | 5.1% | 7.7% | 17.1% | 11.2% | 10.0% | 12.3% | 18.5% | 13.3% | 13.0% | 16.4% | 40.5% | 32.5% |
| Net profit | 615 Cr | 604 Cr | 304 Cr | 550 Cr | 702 Cr | 641 Cr | 322 Cr | 668 Cr | 779 Cr | 653 Cr | 251 Cr | 521 Cr |
| EPS (₹) | ₹51.90 | ₹49.76 | ₹24.55 | ₹45.60 | ₹57.60 | ₹52.34 | ₹25.57 | ₹55.56 | ₹63.99 | ₹53.19 | ₹19.77 | ₹43.49 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019BSE balance sheet (this exchange's own filing had none for this period) | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021 | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 7,357 Cr | 8,344 Cr | 8,865 Cr | 10,634 Cr | 11,599 Cr | 12,668 Cr | 12,965 Cr | 14,712 Cr | Sign in for TTM |
| Operating expenses (approx.) | 6,242 Cr | 6,871 Cr | 6,923 Cr | 8,581 Cr | 9,990 Cr | 10,422 Cr | 10,452 Cr | 11,707 Cr | Sign in for TTM |
| EBITDA | 1,115 Cr | 1,473 Cr | 1,942 Cr | 2,053 Cr | 1,609 Cr | 2,245 Cr | 2,512 Cr | 3,005 Cr | Sign in for TTM |
| OPM % | 15.2% | 17.7% | 21.9% | 19.3% | 13.9% | 17.7% | 19.4% | 20.4% | Sign in for TTM |
| Other income | 88 Cr | 104 Cr | 233 Cr | 163 Cr | 216 Cr | 311 Cr | 494 Cr | 583 Cr | Sign in for TTM |
| Interest | 55 Cr | 65 Cr | 59 Cr | 52 Cr | 107 Cr | 112 Cr | 122 Cr | 161 Cr | Sign in for TTM |
| Depreciation | 193 Cr | 253 Cr | 275 Cr | 304 Cr | 310 Cr | 299 Cr | 357 Cr | 382 Cr | Sign in for TTM |
| Profit before tax | 955 Cr | 1,260 Cr | 1,842 Cr | 1,844 Cr | 1,305 Cr | 2,023 Cr | 2,526 Cr | 2,869 Cr | Sign in for TTM |
| Tax % | 19.0% | 8.8% | 12.2% | 8.9% | 22.8% | 10.5% | 12.3% | 18.0% | Sign in for TTM |
| Net profit | 774 Cr | 1,149 Cr | 1,618 Cr | 1,680 Cr | 1,007 Cr | 1,811 Cr | 2,215 Cr | 2,351 Cr | Sign in for TTM |
| EPS (₹) | ₹63.61 | ₹94.26 | ₹132.57 | ₹137.63 | ₹82.31 | ₹150.19 | ₹181.11 | ₹192.51 | Sign in for TTM |
| Dividend payout % | — | — | — | 25.1% | 52.6% | 29.8% | 22.8% | 26.1% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019BSE balance sheet (this exchange's own filing had none for this period) | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021 | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 24 Cr | 24 Cr | 24 Cr | 24 Cr | 24 Cr | 24 Cr | 24 Cr | 24 Cr |
| Reserves | 5,415 Cr | 6,137 Cr | 7,353 Cr | 8,614 Cr | 9,021 Cr | 10,288 Cr | 11,961 Cr | 13,796 Cr |
| Borrowings | 903 Cr | 1,663 Cr | 1,670 Cr | 2,668 Cr | 1,397 Cr | 1,214 Cr | 1,063 Cr | 1,624 Cr |
| Other liabilities | 1,734 Cr | 1,972 Cr | 2,291 Cr | 2,554 Cr | 2,925 Cr | 3,647 Cr | 4,195 Cr | 4,901 Cr |
| Total liabilities | 8,208 Cr | 9,943 Cr | 11,519 Cr | 14,069 Cr | 13,757 Cr | 15,575 Cr | 17,691 Cr | 20,873 Cr |
| Fixed assets (net) | 2,106 Cr | 2,306 Cr | 2,234 Cr | 2,287 Cr | 2,065 Cr | 2,161 Cr | 2,064 Cr | 2,695 Cr |
| CWIP | 493 Cr | 363 Cr | 393 Cr | 339 Cr | 310 Cr | 148 Cr | 477 Cr | 138 Cr |
| Investments | 324 Cr | 261 Cr | 333 Cr | 371 Cr | 622 Cr | 484 Cr | 1,846 Cr | 1,869 Cr |
| Loans & advances | 31 Cr | 28 Cr | 31 Cr | 20 Cr | 7 Cr | 9 Cr | 9 Cr | 7 Cr |
| Inventories | 1,500 Cr | 1,819 Cr | 2,312 Cr | 3,006 Cr | 2,608 Cr | 2,661 Cr | 2,922 Cr | 3,333 Cr |
| Trade receivables | 1,248 Cr | 1,649 Cr | 1,607 Cr | 1,885 Cr | 2,132 Cr | 2,253 Cr | 2,466 Cr | 2,979 Cr |
| Cash & bank | 249 Cr | 176 Cr | 174 Cr | 232 Cr | 274 Cr | 455 Cr | 304 Cr | 248 Cr |
| Other assets | 2,258 Cr | 3,341 Cr | 4,434 Cr | 5,929 Cr | 5,739 Cr | 7,403 Cr | 7,603 Cr | 9,604 Cr |
| Total assets | 8,208 Cr | 9,943 Cr | 11,519 Cr | 14,069 Cr | 13,757 Cr | 15,575 Cr | 17,691 Cr | 20,873 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019BSE balance sheet (this exchange's own filing had none for this period) | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021 | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 1,111 Cr | 1,683 Cr | 1,948 Cr | 1,913 Cr | 1,963 Cr |
| Cash from investing | — | — | — | -1,435 Cr | 113 Cr | -1,009 Cr | -1,299 Cr | -1,667 Cr |
| Cash from financing | — | — | — | 380 Cr | -1,761 Cr | -1,145 Cr | -811 Cr | -503 Cr |
| Net cash flow | — | — | — | 58 Cr | 42 Cr | -207 Cr | -186 Cr | -222 Cr |
| Free cash flow (OCF − Capex) | — | — | — | 772 Cr | 1,450 Cr | 1,689 Cr | 1,237 Cr | 1,346 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019BSE balance sheet (this exchange's own filing had none for this period) | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021 | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 18.6% | 16.6% | 20.6% | 22.0% | 13.0% | 17.9% | 19.6% | 19.0% |
| ROE % | 14.0% | 19.1% | 21.0% | 19.1% | 10.4% | 16.8% | 17.4% | 16.0% |
| Debtor days | 62 | 72 | 66 | 65 | 67 | 65 | 69 | 74 |
| Inventory days | 301 | 311 | 352 | 339 | 310 | 295 | 309 | 340 |
| Days payable | 193 | 163 | 163 | 132 | 139 | 194 | 195 | 229 |
| Cash conversion cycle | 170 | 220 | 255 | 271 | 239 | 166 | 184 | 185 |
| Debt / equity | 0.17 | 0.27 | 0.23 | 0.31 | 0.15 | 0.12 | 0.09 | 0.12 |
| Current ratio | 1.92 | 1.69 | 1.92 | 1.76 | 2.32 | 2.61 | 2.73 | 2.55 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.77 | 0.00 | 0.70 | 0.34 | 0.30 | 0.46 |
Compare with peers
Loading peers…